RxDoctor Payments Data

Luis Hernandez Rodriguez, MD

General Practice · Orlando, FLNPI 1245979160

Payments from drug & device makers

$1,488in general payments, 2019–2025

Across 77 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$273
  • Novo Nordisk$230
  • Amgen$225
  • Lilly USA, LLC$195
  • Boehringer Ingelheim$190
  • Exact Sciences$127
  • plus $248 from 8 others

What the payments were for

  • Food & beverage$1,45698%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,488 in reported general payments places this provider in the 85th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$7,976
Medicare patients
25
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$103,712
OzempicSemaglutide91$100,038
JardianceEmpagliflozin64$66,501
FarxigaDapagliflozin Propanediol63$55,065
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$33,078
JanuviaSitagliptin Phosphate17$24,830
TrulicityDulaglutide18$19,596
VraylarCariprazine Hcl12$16,510
Tresiba Flextouch U-100Insulin Degludec23$14,932
MounjaroTirzepatide14$14,842
RybelsusSemaglutide11$11,665
LinzessLinaclotide14$7,450
SymbicortBudesonide/Formoterol Fumarate20$6,284
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$5,403
Albuterol Sulfate HfaAlbuterol Sulfate167$4,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$230$111,704102 claims
PfizerEliquis$27$103,71286 claims
Boehringer IngelheimJardiance$190$66,50164 claims
AstraZenecaFarxiga, Symbicort$273$61,34983 claims
Lilly USA, LLCTrulicity, Mounjaro$195$34,43732 claims
GSKTrelegy Ellipta$70$33,07829 claims
MerckJanuvia$15$24,83017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,901 general practice providers in Florida.

Other general practice in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →